- Home
- NBIX vs TXRH Comparison
NBIX vs TXRH Comparison
Compare NBIX & TXRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NBIX | TXRH |
|---|---|---|
| Founded | 1992 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4B | 11.0B |
| IPO Year | 1996 | 2004 |
Fundamental Metrics
Financial Performance| Metric | NBIX | TXRH |
|---|---|---|
| Price | $155.51 | $165.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 17 |
| Target Price | $173.79 | ★ $189.47 |
| AVG Volume (30 Days) | 969.9K | ★ 1.0M |
| Earning Date | 10-28-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 1.64% |
| EPS Growth | 12.44 | ★ 12.56 |
| EPS | 4.19 | ★ 6.55 |
| Revenue | $2,682,700,000.00 | ★ $5,833,958,000.00 |
| Revenue This Year | $23.76 | $11.90 |
| Revenue Next Year | $18.01 | $10.41 |
| P/E Ratio | $37.10 | ★ $25.38 |
| Revenue Growth | ★ 19.61 | 14.40 |
| 52 Week Low | $84.23 | $148.73 |
| 52 Week High | $157.67 | $199.99 |
Technical Indicators
Market Signals| Indicator | NBIX | TXRH |
|---|---|---|
| Relative Strength Index (RSI) | 64.81 | 44.55 |
| Support Level | $150.26 | $165.70 |
| Resistance Level | $154.35 | $178.68 |
| Average True Range (ATR) | 4.16 | 3.80 |
| MACD | 1.07 | -0.42 |
| Stochastic Oscillator | 93.25 | 3.70 |
Price Performance
Historical ComparisonAbout NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
About TXRH Texas Roadhouse Inc.
Texas Roadhouse Inc is a restaurant company operating predominantly in the casual dining segment. The company manages its restaurant and franchising operations by concept and, as a result, has identified Texas Roadhouse, Bubba's 33, Jaggers, and retail initiatives as separate operating segments. In addition, it has identified Texas Roadhouse and Bubba's 33 as reportable segments. Maximum revenue for the company is generated from the Texas Roadhouse segment, which is a moderately priced, full-service, casual dining restaurant concept offering steaks, a selection of ribs, seafood, chicken, pork chops, pulled pork, vegetable plates, and an assortment of hamburgers, salads, and sandwiches.